Skip to main content
N

NOXOPHARM LIMITED — Investor Relations & Filings

Ticker · NOX ISIN · AU000000NOX9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 62 across all filing types
Latest filing 2026-04-26 Regulatory Filings
Country AU Australia
Listing ASX NOX

About NOXOPHARM LIMITED

https://www.noxopharm.com

Noxopharm Limited is a clinical-stage drug development company focused on the discovery and development of novel treatments for cancer and inflammation. The company utilizes its proprietary drug discovery platforms, including Chroma and Sofra, to create a pipeline of therapeutic candidates. Its lead oncology asset, Veyonda, is designed to function as a radio-enhancer and chemo-sensitizer, aiming to improve the efficacy of existing cancer treatments. Additionally, the Sofra platform focuses on the development of synthetic oligonucleotides to modulate the immune system, specifically targeting toll-like receptors 7 and 8 to treat autoimmune and inflammatory diseases. Noxopharm also explores applications in mRNA vaccine technology through its SOF-VAC program, which aims to reduce the inflammatory side effects associated with mRNA-based therapeutics.

Recent filings

Filing Released Lang Actions
Innovative collaboration further expands Sofra platform 3 pages 418.4KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing collaboration results on the Sofra™ platform with InhaTarget Therapeutics, containing study highlights, market context, and forward-looking statements. It is not an earnings release, financial report, dividend notice, management change, or other specific filing type. It does not attach or announce publication of a separate formal report. Therefore, it falls under the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-04-26 English
March 2026 Quarterly Activities Report and Appendix 4C 9 pages 698.0KB
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Activities Report and Appendix 4C' for Noxopharm Limited. It contains both a narrative update on company activities (R&D, management changes, clinical trials) and the mandatory ASX Appendix 4C cash flow statement, which provides substantive financial data for the quarter ending 31 March 2026. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial and operational performance for a period shorter than a full fiscal year. Q3 2026
2026-04-23 English
Positive SOF-SKN dosing data shows prolonged skin retention 4 pages 431.7KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release by Noxopharm announcing new preclinical dosing data for their SOF-SKN™ drug candidate. It is not a financial report (Annual, Quarterly/Interim, or Earnings Release), nor an investor presentation, capital update, governance filing, or any other specialized category. It contains substantive content rather than just notice of a report publication. Therefore the appropriate classification is the fallback category ‘Regulatory Filings’ (RNS).
2026-04-21 English
Change of & Final Directors Interest Notice (App 3Y & 3Z)-GM 6 pages 425.2KB
Director's Dealing Classification · 1% confidence The document is styled as ASX Appendix 3Y (Change of Director’s Interest Notice) and Appendix 3Z (Final Director’s Interest Notice) disclosing Dr Gisela Mautner’s personal security holdings and changes (lapsing options, approved future issue). This is a report of insider share transactions and director interests. It matches the definition for Director’s Dealing (DIRS).
2026-04-14 English
Noxopharm appoints Dr Olivier Laczka as new CEO 3 pages 331.0KB
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new CEO, detailing his background, employment terms, and option grant. This is an announcement of a change in senior management rather than a financial report, call transcript, or regulatory filing. It directly falls under the category of Board/Management Information (MANG).
2026-04-14 English
Resignation of Chief Executive Officer 2 pages 286.4KB
Regulatory Filings
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.